% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pohl:275751,
      author       = {S. Pohl and L. Dimitrova and M. Grassow-Narlik and K.
                      Jöhrens and T. Acker and H. Dohmen and J. Herms and M.
                      Dorostkar and C. Hartmann and M. Hasselblatt and M. Neumann
                      and G. Reifenberger$^*$ and J. Felsberg and U. Schüller and
                      S. Zoubaa and J. Lorenz and T. Rothhammer-Hampl and K.
                      Mauch-Mücke and M. J. Riemenschneider},
      title        = {{U}pdate on quality assurance in neuropathology: {S}ummary
                      of the round robin trials on {TERT} promoter mutation,
                      {H}3-3{A} mutation, 1p/19q codeletion, and
                      {KIAA}1549::{BRAF} fusion testing in {G}ermany in 2020 and
                      2021},
      journal      = {Clinical neuropathology},
      volume       = {42},
      issn         = {0722-5091},
      address      = {Deisenhofen, München},
      publisher    = {Dustri-Verl.},
      reportid     = {DKFZ-2023-00850},
      pages        = {112 - 121},
      year         = {2023},
      abstract     = {We previously reported on the first neuropathological round
                      robin trials operated together with Quality in Pathology
                      (QuIP) GmbH in 2018 and 2019 in Germany, i.e., the trials on
                      IDH mutational testing and MGMT promoter methylation
                      analysis [1]. For 2020 and 2021, the spectrum of round robin
                      trials has been expanded to cover the most commonly used
                      assays in neuropathological institutions. In addition to IDH
                      mutation and MGMT promoter methylation testing, there is a
                      long tradition for 1p/19q codeletion testing relevant in the
                      context of the diagnosis of oligodendroglioma. With the 5th
                      edition of the World Health Organization (WHO)
                      classification of the central nervous system tumors,
                      additional molecular markers came into focus: TERT promoter
                      mutation is often assessed as a molecular diagnostic
                      criterion for IDH-wildtype glioblastoma. Moreover, several
                      molecular diagnostic markers have been introduced for
                      pediatric brain tumors. Here, trials on KIAA1549::BRAF
                      fusions (common in pilocytic astrocytomas) and H3-3A
                      mutations (in diffuse midline gliomas, H3-K27-altered and
                      diffuse hemispheric gliomas, H3-G34-mutant) were most
                      desired by the neuropathological community. In this update,
                      we report on these novel round robin trials. In summary,
                      success rates in all four trials ranged from 75 to $96\%,$
                      arguing for an overall high quality level in the field of
                      molecular neuropathological diagnostics.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.5414/NP301547},
      url          = {https://inrepo02.dkfz.de/record/275751},
}